[Amazon.com Inc.] likely has few options remaining for extending its Solimo dietary supplement and Basic Care OTC drug brand lines but both are positioned to gain market share with product prices cut lower in the past six months than the biggest private label and store brand competitors.
“There just aren’t a lot of products left that they could launch in the health care bucket that they don’t offer today” in the Solimo line, said Jefferies Americas market analyst Brian Tanquilut in an interview following his Dec. 27 report on Amazon brands' sales
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?